Clinical trial
Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176423 · University of Maryland, Baltimore, Other · Completed
Key facts
| NCT number | NCT00176423 |
|---|---|
| Title | Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia |
| Official title | Adjunctive Galantamine for Treatment of Cognitive Impairments in Patients With Schizophrenia |
| Lead sponsor | University of Maryland, Baltimore, Other |
| Collaborators | Stanley Medical Research Institute Ortho-McNeil Neurologics, Inc. Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia, Schizoaffective Disorder |
| Intervention type | Drug |
| Interventions | galantamine |
| Enrollment | 117 |
| Start date | May 1, 2002 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Sep 15, 2005 |
| Last update posted | Dec 16, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: